Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study.

Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A; EXTEND Study Group.

Blood. 2013 Jan 17;121(3):537-45. doi: 10.1182/blood-2012-04-425512. Epub 2012 Nov 20.

2.

Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.

Grainger JD, Locatelli F, Chotsampancharoen T, Donyush E, Pongtanakul B, Komvilaisak P, Sosothikul D, Drelichman G, Sirachainan N, Holzhauer S, Lebedev V, Lemons R, Pospisilova D, Ramenghi U, Bussel JB, Bakshi KK, Iyengar M, Chan GW, Chagin KD, Theodore D, Marcello LM, Bailey CK.

Lancet. 2015 Oct 24;386(10004):1649-58. doi: 10.1016/S0140-6736(15)61107-2. Epub 2015 Jul 28. Erratum in: Lancet. 2015 Oct 24;386(10004):1630.

PMID:
26231455
3.

A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia.

Tomiyama Y, Miyakawa Y, Okamoto S, Katsutani S, Kimura A, Okoshi Y, Ninomiya H, Kosugi H, Nomura S, Ozaki K, Ikeda Y, Hattori T, Katsura K, Kanakura Y.

J Thromb Haemost. 2012 May;10(5):799-806. doi: 10.1111/j.1538-7836.2012.04695.x.

4.

Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study.

Katsutani S, Tomiyama Y, Kimura A, Miyakawa Y, Okamoto S, Okoshi Y, Ninomiya H, Kosugi H, Ishii K, Ikeda Y, Hattori T, Katsura K, Kanakura Y.

Int J Hematol. 2013 Sep;98(3):323-30. doi: 10.1007/s12185-013-1401-1. Epub 2013 Jul 30.

PMID:
23896965
5.

Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.

Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, Arning M, Provan D, Jenkins JM.

N Engl J Med. 2007 Nov 29;357(22):2237-47.

6.

Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.

Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, Stone N, Arning M.

Lancet. 2009 Feb 21;373(9664):641-8. doi: 10.1016/S0140-6736(09)60402-5.

PMID:
19231632
7.

Use of eltrombopag after romiplostim in primary immune thrombocytopenia.

González-Porras JR, Mingot-Castellano ME, Andrade MM, Alonso R, Caparrós I, Arratibel MC, Fernández-Fuertes F, Cortti MJ, Pascual C, Sánchez-González B, Bernat S, Fuertes-Palacio MA, Vázquez-Paganini JA, Olivera PE, Alvarez-Román MT, Jarque I, Cortés M, Martínez-Robles V, Díaz-Gálvez FJ, Calbacho M, Fernández-Miñano C, Garcia-Frade J, González-López TJ.

Br J Haematol. 2015 Apr;169(1):111-6. doi: 10.1111/bjh.13266. Epub 2014 Dec 18.

PMID:
25521630
8.

Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study.

Kawaguchi T, Komori A, Seike M, Fujiyama S, Watanabe H, Tanaka M, Sakisaka S, Nakamuta M, Sasaki Y, Oketani M, Hattori T, Katsura K, Sata M.

J Gastroenterol. 2012 Dec;47(12):1342-51. doi: 10.1007/s00535-012-0600-5. Epub 2012 Jun 8.

9.

Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.

Garnock-Jones KP.

BioDrugs. 2011 Dec 1;25(6):401-4. doi: 10.2165/11207620-000000000-00000. Review.

PMID:
22050343
10.

Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.

Bussel JB, de Miguel PG, Despotovic JM, Grainger JD, Sevilla J, Blanchette VS, Krishnamurti L, Connor P, David M, Boayue KB, Matthews DC, Lambert MP, Marcello LM, Iyengar M, Chan GW, Chagin KD, Theodore D, Bailey CK, Bakshi KK.

Lancet Haematol. 2015 Aug;2(8):e315-25. doi: 10.1016/S2352-3026(15)00114-3. Epub 2015 Jul 28. Erratum in: Lancet Haematol. 2015 Oct;2(10):e407.

PMID:
26688484
11.

Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia.

Yang R, Li J, Jin J, Huang M, Yu Z, Xu X, Zhang X, Hou M.

Br J Haematol. 2017 Jan;176(1):101-110. doi: 10.1111/bjh.14380. Epub 2016 Oct 13.

PMID:
27734464
12.

Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia.

Garnock-Jones KP.

Drugs. 2011 Jul 9;71(10):1333-53. doi: 10.2165/11207390-000000000-00000. Review.

PMID:
21770480
13.

Population Pharmacokinetic and Pharmacodynamic Modeling and Effects on Platelet Counts of Different Dosages of Eltrombopag in Chinese Patients With Chronic Primary Immune Thrombocytopenia.

Wu K, Thapar M, Farrell C, Hayes S, Guo H, Hou M, Zhang J.

Clin Ther. 2015 Jul 1;37(7):1382-95. doi: 10.1016/j.clinthera.2015.03.024. Epub 2015 Apr 27.

PMID:
25929594
14.

Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.

González-López TJ, Pascual C, Álvarez-Román MT, Fernández-Fuertes F, Sánchez-González B, Caparrós I, Jarque I, Mingot-Castellano ME, Hernández-Rivas JA, Martín-Salces M, Solán L, Beneit P, Jiménez R, Bernat S, Andrade MM, Cortés M, Cortti MJ, Pérez-Crespo S, Gómez-Núñez M, Olivera PE, Pérez-Rus G, Martínez-Robles V, Alonso R, Fernández-Rodríguez A, Arratibel MC, Perera M, Fernández-Miñano C, Fuertes-Palacio MA, Vázquez-Paganini JA, Gutierrez-Jomarrón I, Valcarce I, de Cabo E, Sainz A, Fisac R, Aguilar C, Paz Martínez-Badas M, Peñarrubia MJ, Calbacho M, de Cos C, González-Silva M, Coria E, Alonso A, Casaus A, Luaña A, Galán P, Fernández-Canal C, Garcia-Frade J, González-Porras JR.

Am J Hematol. 2015 Mar;90(3):E40-3. doi: 10.1002/ajh.23900. Epub 2015 Jan 16.

15.

Eltrombopag.

Garnock-Jones KP, Keam SJ.

Drugs. 2009;69(5):567-76. doi: 10.2165/00003495-200969050-00005.

PMID:
19368418
16.

Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.

González-López TJ, Alvarez-Román MT, Pascual C, Sánchez-González B, Fernández-Fuentes F, Jarque I, Pérez-Rus G, Pérez-Crespo S, Bernat S, Hernández-Rivas JA, Andrade MM, Cortés M, Gómez-Nuñez M, Olivera P, Martínez-Robles V, Fernández-Rodríguez A, Fuertes-Palacio MA, Fernández-Miñano C, de Cabo E, Fisac R, Aguilar C, Bárez A, Peñarrubia MJ, García-Frade LJ, González-Porras JR.

Eur J Haematol. 2016 Sep;97(3):297-302. doi: 10.1111/ejh.12725. Epub 2016 Jan 27.

PMID:
26709028
17.

Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP).

Bussel JB, Saleh MN, Vasey SY, Mayer B, Arning M, Stone NL.

Br J Haematol. 2013 Feb;160(4):538-46. doi: 10.1111/bjh.12169. Epub 2012 Dec 24.

PMID:
23278590
18.

Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study.

Brynes RK, Orazi A, Theodore D, Burgess P, Bailey CK, Thein MM, Bakshi KK.

Am J Hematol. 2015 Jul;90(7):598-601. doi: 10.1002/ajh.24011.

19.

Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia.

González-López TJ, Sánchez-González B, Pascual C, Arefi M, de Cabo E, Alonso A, Martín-Salces M, Jiménez-Bárcenas R, Calbacho M, Galan P, Barez A, González-Porras JR.

Platelets. 2015;26(1):83-6. doi: 10.3109/09537104.2013.870987. Epub 2014 Feb 5.

PMID:
24499036
20.

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.

Svensson T, Chowdhury O, Garelius H, Lorenz F, Saft L, Jacobsen SE, Hellström-Lindberg E, Cherif H.

Eur J Haematol. 2014 Nov;93(5):439-45. doi: 10.1111/ejh.12383. Epub 2014 Jun 14.

PMID:
24853277

Supplemental Content

Support Center